scholarly journals Patchy Alopecia in a Patient with Rheumatoid Arthritis: A Practical Application of Trichoscopy

2021 ◽  
pp. 42-46
Author(s):  
Ahmad Vafaeian ◽  
Elham Taghizadeh ◽  
Maryam Daneshpazhooh ◽  
Hamidreza Mahmoudi
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Tinea Capitis ◽  
Skin Diseases ◽  
Cutaneous Lupus Erythematosus ◽  
Proper Treatment ◽  
Practical Application ◽  
History Of ◽  
Cutaneous Lupus

Trichoscopy is an efficient, convenient, and accurate diagnostic dermatological procedure which is widely used in the examination of patients with skin diseases. Herein, we report a 56-year-old woman with a long-term history of rheumatoid arthritis complaining of pruritic patchy alopecia on her scalp who was referred for biopsy to exclude cutaneous lupus erythematosus. Taking advantage of trichoscopy, we were able to quickly diagnose tinea capitis. Following administration of the proper treatment the disease resolved completely.

Drug-induced subacute cutaneous lupus erythematosus associated with abatacept

Lupus ◽  
2020 ◽  
pp. 096120332098114
Author(s):  
Eliana Figueredo Zamora ◽  
Jeffrey P Callen ◽  
Courtney R Schadt
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Time Course ◽  
Cutaneous Lupus Erythematosus ◽  
Clinical Findings ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Drug Induced ◽  
The Third ◽  
History Of ◽  
Cutaneous Lupus

Numerous drugs have been linked to the induction or exacerbation of systemic cutaneous lupus erythematosus (SCLE). This report presents the third case of the biologic abatacept as an exacerbating medication for SCLE. A 73-year old woman with a remote history of subacute cutaneous lupus and rheumatoid arthritis, well controlled on hydroxychloroquine, presented with worsening annular erythematous, slightly scaly plaques on her forearms and hands. She had been started on abatacept a month prior. She was diagnosed with SCLE exacerbated by abatacept given the clinical findings, time course, and skin biopsy with interface dermatitis. Her skin eruption cleared completely several months later after discontinuing abatacept and switching to tociluzumab, while remaining on hydroxychloroquine. This case highlights the need to consider abatacept as a potential exacerbating medication for SCLE in any patient with a new photodistributed papulosquamous eruption.

Subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis

2002 ◽  
Vol 31 (6) ◽  
pp. 377-379 ◽  
Author(s):  
Lucia Pantoja ◽  
Marcos Antonio González-López ◽  
Marta Bouso ◽  
Antonio Alija ◽  
Juan Ortiz-Saracho
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Cutaneous Lupus

scholarly journals Capecitabine-Induced Subacute Cutaneous Lupus Erythematosus in a Patient with Systemic Lupus Erythematosus

2018 ◽  
Vol 2 (1) ◽  
pp. 59-63
Author(s):  
Alyx Rosen ◽  
Evan Darwin ◽  
Jennifer N Choi
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Metastatic Breast ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Systemic Lupus ◽  
Drug Induced ◽  
Increased Risk ◽  
History Of ◽  
Cutaneous Lupus

Capecitabine is a fluoropyrimidine chemotherapy prodrug of 5-fluorouracil (5-FU) used in the treatment of metastatic breast and colorectal cancers. Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is a rare side effect of capecitabine therapy, with eight cases previously reported. We report a case of DI-SCLE in a patient with a documented history of systemic lupus erythematosus (SLE). This is the second documented case of DI-SCLE in a patient with a past medical history of SLE, and provides evidence that there may be an increased risk of DI-SCLE in these patients. Further research should examine whether patients with SLE are at greater risk for this adverse event. 

scholarly journals Fractures in Corticosteroid- and Bisphosphonate-treated Subjects With Longstanding Rheumatoid Arthritis

2021 ◽  
Author(s):  
Atie Moghtadaie ◽  
Seyed Amir Miratashi Yazd ◽  
Ahmad Salimzadeh
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Femoral Fractures ◽  
Bone Diseases ◽  
Multiple Fractures ◽  
Metabolic Bone Diseases ◽  
Atypical Femoral Fractures ◽  
Therapy Assessment ◽  
History Of

Background: Bisphosphonates are the most widely prescribed agents for the treatment of postmenopausal osteoporosis and other metabolic bone diseases. Atypical femoral fractures in bisphosphonate-treated patients have raised concerns regarding the long-term safety of this class of medications. Case Presentation: In this study, we report two patients suffering from fractures while receiving biphosphonates; a postmenopausal patient with rheumatoid arthritis and a history of long-term use of bisphosphonates and glucocorticoids presenting with multiple fractures as case one and another 52-year-old female patient diagnosed with Systemic Lupus Erythematosus (SLE) who suffered from a femoral shaft fracture without any history of prior traumatic incidents as case two. Conclusions: Considering the low risk for atypical femoral fractures, further careful screening for these types of fractures should be undertaken. In addition, in order to lower the rate of fractures in patients on long-term bisphosphonate therapy, assessment of patients’ contralateral side should be considered to prevent further fractures, especially in patients with prodromal pain.

Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus

2021 ◽  
Vol 123 ◽  
pp. 102707
Author(s):  
Qianjin Lu ◽  
Hai Long ◽  
Steven Chow ◽  
Syarief Hidayat ◽  
Retno Danarti ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Term Management ◽  
Cutaneous Lupus
Sign in / Sign up

Export Citation Format

Share Document